vs
EXACT SCIENCES CORP（EXAS）与MSC INDUSTRIAL DIRECT CO INC（MSM）财务数据对比。点击上方公司名可切换其他公司
MSC INDUSTRIAL DIRECT CO INC的季度营收约是EXACT SCIENCES CORP的1.1倍（$965.7M vs $878.4M），MSC INDUSTRIAL DIRECT CO INC净利率更高（5.4% vs -9.8%，领先15.2%），EXACT SCIENCES CORP同比增速更快（23.1% vs 4.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $7.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -3.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
MSC工业直销公司（MSC）通过旗下主要子公司MSC工业供应公司，是美国规模最大的工业设备分销商之一，可提供超过150万种金属加工及其他工业类产品，广泛服务于工业制造、维修运维等领域的客户需求。
EXAS vs MSM — 直观对比
营收规模更大
MSM
是对方的1.1倍
$878.4M
营收增速更快
EXAS
高出19.1%
4.0%
净利率更高
MSM
高出15.2%
-9.8%
自由现金流更多
EXAS
多$113.0M
$7.4M
两年增速更快
EXAS
近两年复合增速
-3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $965.7M |
| 净利润 | $-86.0M | $51.8M |
| 毛利率 | 70.1% | 40.7% |
| 营业利润率 | -9.4% | 7.9% |
| 净利率 | -9.8% | 5.4% |
| 营收同比 | 23.1% | 4.0% |
| 净利润同比 | 90.1% | 11.1% |
| 每股收益（稀释后） | $-0.45 | $0.93 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASMSM
| Q4 25 | $878.4M | $965.7M | ||
| Q3 25 | $850.7M | $978.2M | ||
| Q2 25 | $811.1M | $971.1M | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | $928.5M | ||
| Q3 24 | $708.7M | — | ||
| Q2 24 | $699.3M | $979.4M | ||
| Q1 24 | $637.5M | $935.3M |
净利润EXASMSM
| Q4 25 | $-86.0M | $51.8M | ||
| Q3 25 | $-19.6M | $56.5M | ||
| Q2 25 | $-1.2M | $56.8M | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | $46.6M | ||
| Q3 24 | $-38.2M | — | ||
| Q2 24 | $-15.8M | $71.7M | ||
| Q1 24 | $-110.2M | $61.8M |
毛利率EXASMSM
| Q4 25 | 70.1% | 40.7% | ||
| Q3 25 | 68.6% | 40.4% | ||
| Q2 25 | 69.3% | 41.0% | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | 40.7% | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | 40.9% | ||
| Q1 24 | 70.0% | 41.5% |
营业利润率EXASMSM
| Q4 25 | -9.4% | 7.9% | ||
| Q3 25 | -3.0% | 8.6% | ||
| Q2 25 | -0.3% | 8.5% | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | 7.8% | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | 10.9% | ||
| Q1 24 | -16.7% | 9.7% |
净利率EXASMSM
| Q4 25 | -9.8% | 5.4% | ||
| Q3 25 | -2.3% | 5.8% | ||
| Q2 25 | -0.1% | 5.9% | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | 5.0% | ||
| Q3 24 | -5.4% | — | ||
| Q2 24 | -2.3% | 7.3% | ||
| Q1 24 | -17.3% | 6.6% |
每股收益（稀释后）EXASMSM
| Q4 25 | $-0.45 | $0.93 | ||
| Q3 25 | $-0.10 | $1.02 | ||
| Q2 25 | $-0.01 | $1.02 | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | $0.83 | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | $1.27 | ||
| Q1 24 | $-0.60 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $40.3M |
| 总债务越低越好 | — | $214.1M |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.16× |
8季度趋势，按日历期对齐
现金及短期投资EXASMSM
| Q4 25 | $964.7M | $40.3M | ||
| Q3 25 | $1.0B | $56.2M | ||
| Q2 25 | $858.4M | $71.7M | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $57.3M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | $25.9M | ||
| Q1 24 | $652.1M | $22.2M |
总债务EXASMSM
| Q4 25 | — | $214.1M | ||
| Q3 25 | — | $168.8M | ||
| Q2 25 | — | $285.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $289.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $299.8M | ||
| Q1 24 | — | $294.5M |
股东权益EXASMSM
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | $1.4B | ||
| Q1 24 | $3.1B | $1.4B |
总资产EXASMSM
| Q4 25 | $5.9B | $2.5B | ||
| Q3 25 | $5.9B | $2.5B | ||
| Q2 25 | $5.8B | $2.5B | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | $2.5B | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.7B | $2.5B | ||
| Q1 24 | $6.4B | $2.5B |
负债/权益比EXASMSM
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $29.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $7.4M |
| 自由现金流率自由现金流/营收 | 13.7% | 0.8% |
| 资本支出强度资本支出/营收 | 3.6% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 0.57× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASMSM
| Q4 25 | $151.7M | $29.4M | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | $151.6M | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | $101.9M | ||
| Q3 24 | $138.7M | — | ||
| Q2 24 | $107.1M | $143.5M | ||
| Q1 24 | $-82.3M | $78.7M |
自由现金流EXASMSM
| Q4 25 | $120.4M | $7.4M | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | $100.7M | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | $81.7M | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | $114.0M | ||
| Q1 24 | $-120.0M | $53.4M |
自由现金流率EXASMSM
| Q4 25 | 13.7% | 0.8% | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | 10.4% | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | 8.8% | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | 11.6% | ||
| Q1 24 | -18.8% | 5.7% |
资本支出强度EXASMSM
| Q4 25 | 3.6% | 2.3% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | 5.2% | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | 2.2% | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | 3.0% | ||
| Q1 24 | 5.9% | 2.7% |
现金转化率EXASMSM
| Q4 25 | — | 0.57× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.67× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.00× | ||
| Q1 24 | — | 1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
MSM
暂无分部数据
